Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41574-020-00449-y http://scihub22266oqcxt.onion/10.1038/s41574-020-00449-y 33239662!7687210!33239662     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33239662&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Nat+Rev+Endocrinol 2021 ; 17 (2): 71-72 Nephropedia Template TP {{tp|p=33239662|t=2021. COVID-19 alters thinking and management in metabolic diseases |pdf=|usr=}}{{33239662}} gab.com Text COVID-19 alters thinking and management in metabolic diseases JO: Nat Rev Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=33239662 #FOAvip Metabolic diseases emerged as important risk factors for severe COVID-19, but the mechanisms responsible remained unclear for some time. The severity of metabolic diseases was also associated with worse outcomes in patients with COVID-19, forcing clinicians to adjust their thinking on which patients with metabolic disease, but without COVID-19, to prioritize for treatment during and immediately after the pandemic. Twit Text FOAVip COVID-19 alters thinking and management in metabolic diseases ????Nat Rev Endocrinol http://www.kidney.de/pget.php?&tw=1&pmid=33239662 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33239662 #FOAvip English Wikipedia <ref>{{Cite pmid|33239662}}</ref> COVID-19 alters thinking and management in metabolic diseases #MMPMID33239662 le Roux CW Nat Rev Endocrinol 2021[Feb]; 17 (2): 71-72 PMID33239662show ga Metabolic diseases emerged as important risk factors for severe COVID-19, but the mechanisms responsible remained unclear for some time. The severity of metabolic diseases was also associated with worse outcomes in patients with COVID-19, forcing clinicians to adjust their thinking on which patients with metabolic disease, but without COVID-19, to prioritize for treatment during and immediately after the pandemic. |*Delivery of Health Care/methods/organization & administration/standards[MESH] |Air Pressure[MESH] |Autopsy[MESH] |Body Mass Index[MESH] |COVID-19/complications/*epidemiology/pathology/*therapy[MESH] |Cause of Death[MESH] |Comorbidity[MESH] |Endothelium, Vascular/pathology/virology[MESH] |Humans[MESH] |Lung/blood supply/pathology/virology[MESH] |Metabolic Diseases/complications/epidemiology/pathology/*therapy[MESH] |Neovascularization, Pathologic/mortality/pathology/virology[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/epidemiology/therapy[MESH] |Pulmonary Embolism/mortality/pathology/therapy/virology[MESH] |Respiration, Artificial/*methods/standards[MESH] |Respiratory Distress Syndrome/epidemiology/pathology/therapy/virology[MESH] |Risk Factors[MESH]COVID-19 alters thinking and management in metabolic diseases (epmc).pdf DeepDyve Pubget Overpricing